News

All Articles in the Category ‘News’

Cognitive Behavioral Therapy Helps Teens With Concussion-Related Mental Health Problems

A new study published in JAMA Network Open shows that providing cognitive behavioral therapy (CBT) as part of a collaborative care model for youth who have experienced persistent post-concussive symptoms (PPCS) offers a promising treatment to alleviate symptoms and improve functioning.

Every year, an estimated 1.1 to 1.9 million youth suffer a sports-related concussion. Between 20% and 30% of those experience symptoms that last more than 30 days, including mental health challenges such as depression or anxiety. Yet there is a lack of high-quality evidence to guide best practices for the treatment of PPCS in the pediatric population. Read full post »

Seattle Children’s Tri-Cities Clinic Is Moving

To better serve the Tri-Cities and surrounding region, Seattle Children’s Tri-Cities Clinic is moving to a larger, more centrally located clinic location opening March 11, 2021, in Kennewick, WA. The clinic will continue to offer the same pediatric specialties, with more room to help meet the growing need for specialty pediatric care in the region.

The new clinic in Kennewick will open Thursday, March 11, 2021, and will replace the clinic in Richland, WA, which will close for good at the end of the day on Thursday, March 4, 2021.

New Clinic Address: 8232 W. Grandridge Blvd., Kennewick, WA 99336 (near Costco)

Clinic and Appointments: 509-582-1700

Provider to Provider Line: 206-987-7777

Online: seattlechildrens.org/tri-cities Read full post »

Cancer Research at Seattle Children’s Contributes to FDA Approval of CAR T-Cell Immunotherapy for Adults

The U.S. Food and Drug Administration has approved Bristol Myers Squibb’s Breyanzi, a chimeric antigen receptor (CAR) T-cell therapy used to treat adults with certain types of large B-cell lymphoma who have not responded to or who have relapsed after standard treatments.

The approval was supported by research at Seattle Children’s, including the CAR T-cell product, patient product manufacturing for Juno Therapeutics’ TRANSCEND trial and data from the Pediatric Leukemia Adoptive Therapy (PLAT-02) clinical trial.

Read more: “Cancer Research at Seattle Children’s Contributes to FDA Approval of CAR T-Cell Immunotherapy Treatment for Adults with Relapsed or Refractory Large B-Cell Lymphoma,” in On the Pulse, Feb. 8, 2021.

COVID-19 Testing and Vaccination Update as of Feb. 3

Seattle Children’s is currently in Phase 1-A of vaccine distribution, priority group 2. This means Seattle Children’s active community medical staff are now eligible to receive the COVID-19 vaccine at Seattle Children’s. We will let you when the vaccine is available to a wider group of community providers. Please note that community providers who are part of another health system should expect to get their vaccine with their home system rather than Seattle Children’s. Read full post »

Returning to Two Caregivers Allowed in Inpatient Settings

To improve support for our patients and their families/caregivers, while ensuring the highest level of safety for everyone, starting Thursday, Jan. 28, Seattle Children’s began allowing up to two caregivers in inpatient settings. Previously the limit was one caregiver. In our outpatient settings, the caregiver limit remains one.

Please note:

  • Patients in single rooms can have up to two caregivers in their room around the clock.
  • Patients in double rooms can have up to two caregivers in their room during visiting hours (8 a.m. to 8 p.m.) and one caregiver overnight.
  • Patients in ambulatory, urgent care and surgical settings may have one caregiver with them.
  • Patients in the Emergency Department may have up to two caregivers with them.

New Division Chief Evelyn Hsu, MD, Brings Big Changes to Gastroenterology/Hepatology

Evelyn Hsu

Seattle Children’s is pleased to announce that Dr. Evelyn Hsu accepted the position of division chief of Gastroenterology and Hepatology, following a year as acting division chief and a very competitive national search. She also has served as program director of the Transplant Hepatology Fellowship and medical director for Liver Transplantation.

“I’m excited to join this group in an official capacity. My priority is to expand our staff and open up our services to care for more children in our region, while implementing a service model that allows us to scale up in size while continuing to provide excellent care.,” says Hsu. Read full post »

Anti-Racism Organizational Change and Accelerated Equity, Diversity and Inclusion Plan

To realize our vision of becoming an anti-racist and equitable health organization, Seattle Children’s has developed the Anti-Racism Organizational Change (AROC) and Accelerated Equity, Diversity and Inclusion (EDI) Plan. This plan was designed with guidance and support from our workforce, patients and families, community, and trusted and expert leaders on anti-racism work, equity, inclusion and diversity. Read full post »

COVID-19 Testing Update as of Jan. 6, 2021

Patients tested to date: 21,461. Positive: 536 (2.4%). Six patients are in the hospital; others are recovering at home.

 

Breaking the Status Quo in Pediatric Disease Research

Seattle Children’s is excited to announce the launch of a novel nonprofit research group that will accelerate the development of new medicines for childhood cancer and other debilitating pediatric diseases.

The new enterprise, Seattle Children’s Therapeutics, reimagines what a pediatric research organization should look like. It is intentionally structured like a biotech company rather than a typical academic research group. The people and functions needed to bring new medicines from bench to bedside — research scientists in the lab, clinical trials management teams, regulatory compliance specialists, business managers and a state-of-the-art on-site facility for manufacturing cellular and genetic therapeutics — have been brought together under one roof, under one management and leadership team.

Seattle Children’s Therapeutics includes a team of 130 led by Dr. Michael Jensen, Seattle Children’s chief therapeutics officer. A renowned pediatric cancer researcher and former founding scientist at Juno Therapeutics, Jensen says Seattle Children’s is “breaking the status quo” of pediatric disease research. Read full post »

North Clinic in Everett Now Offers Psychiatry and Behavioral Medicine

Outpatient psychiatry services are now available at Seattle Children’s North Clinic in Everett. Providers at the North Clinic are offering:

  • Diagnostic evaluations for depression, anxiety and early childhood disorders
  • Stepped-care treatment for anxiety and externalizing behaviors (focusing on groups with some individual/family therapy)
  • Parent management training
  • Individual therapy for depressive disorders (very limited; by internal referral only)
  • Treatment of young children focusing on parent management training

Read full post »